<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097356</url>
  </required_header>
  <id_info>
    <org_study_id>2414VV</org_study_id>
    <nct_id>NCT01097356</nct_id>
  </id_info>
  <brief_title>The Effect of Probiotics on the Clearance of the Human Papillomavirus and on Cytological Lesions Caused by the Virus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: In this project proposition the investigators would like to examine the effect of immune&#xD;
      modulation by probiotics on the clearance of HPV-infections.&#xD;
&#xD;
      This study provides a model for viral infection but also for cancer precursors. This would be&#xD;
      an excellent model (and the only possible short-term model) to examine an effect on cancer&#xD;
      precursors. Cancer precursors (cytological abnormalities such as L-SIL) are a scientifically&#xD;
      accepted surrogate endpoint for cervical cancer, for example in HPV-vaccine studies.&#xD;
&#xD;
      Research question: Does daily intake of probiotics lead to a better immune-response in&#xD;
      HPV-infected women, i.e. does it facilitate clearance of the virus and/or regression of&#xD;
      cytological lesions?&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.proportion of HPV positives in both arms</measure>
    <time_frame>6months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>2. proportion of regression of LSIL lesion in both arms</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HPV-related Cytological Abnormalities on PAP Smear (LSIL)</condition>
  <arm_group>
    <arm_group_label>common care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>probiotic drinkers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV+, LSIL patients who will drink the study drink for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic drinkers</intervention_name>
    <description>HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months</description>
    <arm_group_label>probiotic drinkers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women with a new LSIL diagnosis an HPV positivity on PAP smear&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women over 65&#xD;
&#xD;
          -  immunocompromised patients (because of disease or drugs)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>veronique verhoeven, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veronique Verhoeven</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Veronique Verhoeven</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

